Table 1.
Clinical characteristics of the study patients (n = 303); shown are numbers (%) or mean with (S.d.)
| Patients | n (%) | Female, n (%) | Mean age, years | No medication, n (%) | GC, n (%) | MTX, n (%) | AZA, n (%) | MMF, n (%) | TNFi, n (%) | JAKi, n (%) | TOZ, n (%) | IL-17i, n (%) | ABA, n (%) | RTX, n (%) | BEL, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 303 | 200 (66) | 61.4 (14.6) | 24 (7.9) | 149 (49.2) | 111 (37) | 19 (6.3) | 24 (7.9) | 70 (23.1) | 22 (7.3) | 7 (2.3) | 19 (6.3) | 17 (5.6) | 29 (9.6) | 5 (1.7) |
| Rheumatoid arthritis | 127 (41.9) | 91 (71.7) | 67 (13.1) | 5 (3.9) | 76 (59.8) | 70 (55.1) | 2 (1.6) | — | 35 (27.6) | 13 (10.2) | 2 (1.6) | — | 17 (13.4) | 20 (15.7) | — |
| Spondyloarthritisa | 75 (24.8) | 37 (49.3) | 56 (14.1) | 6 (8) | 11 (14.7) | 25 (33.3) | — | — | 35 (46.7) | 3 (4) | — | 19 (25.3) | — | — | — |
| Connective tissue diseases | 71 (23.4) | 57 (83.1) | 56.3 (14.6) | 11 (15.5) | 39 (54.9) | 7 (9.9) | 15 (20.8) | 23 (31.9) | — | 6 (8.3) | — | — | — | 1 (1.4) | 5 (7.0) |
| Systemic lupus erythematosus | 57 (18.8) | 47 (82.5) | 53.3 (13.7) | 5 (8.8) | 34 (59.6) | 5 (8.8) | 13 (22.8) | 21 (36.8) | — | 6 (10.5) | — | — | — | 1 (1.8) | 5 (8.8) |
| ANCA-associated vasculitis | 17 (5.6) | 7 (41.2) | 63.7 (12.9) | 1 (5.9) | 16 (94.1) | 5 (29.4) | 2 (11.8) | — | — | — | — | — | — | 7 (41.2) | — |
| Large-vessel vasculitis | 7 (2.3) | 3 (42.9) | 69 (13.2) | — | 6 (85.7) | 2 (28.6) | — | 1b (14.3) | — | — | 4 (57.1) | — | — | — | — |
| Adult-onset Still’s disease | 3 (1) | 1 (33.3) | 59 (15.1) | — | — | 2 (66.7) | — | — | — | — | 1 (33.3) | — | — | 1 (33.3) | — |
| Idiopathic juvenile arthritis | 2 (0.7) | 2 (100) | 46 (14.1) | 1 (50) | 1 (50) | — | — | — | — | — | — | — | — | — | — |
a
Including axial spondyloarthritis and psoriatic arthritis.
b
MMF is prescribed for a coincidental autoimmune hepatitis.
ABA: abatacept; BEL: belimumab; GC: glucocorticoids; IL-17i: IL17 inhibitor; JAKi: JAK inhibitor; RTX: rituximab; TNFi: TNF inhibitor; TOZ: tocilizumab.